A study was conducted to demonstrate performance comparability of salbutamol sulphate soft mist aerosols delivered from a clinical specific single use Pulmospray™ and commercially available multidose prefilled syringe soft mist inhaler (PFSI™) being developed by Resyca®.
We showcased the results of this study at DDL 2024, incase you missed it, fill out your details to be sent the poster.
